Unknown

Dataset Information

0

A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.


ABSTRACT: To address the therapeutic challenges in childhood relapsed ALL, a phase 1 study combining a survivin mRNA antagonist, EZN-3042, with reinduction chemotherapy was developed for pediatric patients with second or greater bone marrow relapses of B-lymphoblastic leukemia. EZN-3042 was administered as a single agent on days -5 and -2 and then in combination with a 4-drug reinduction platform on days 8, 15, 22, and 29. Toxicity and the biological activity of EZN-3042 were assessed. Six patients were enrolled at dose level 1 (EZN-3042 2.5 mg/kg/dose). Two dose-limiting toxicities were observed: 1 patient developed a grade 3 ?-glutamyl transferase elevation and another patient developed a grade 3 gastrointestinal bleeding. Downmodulation of survivin mRNA and protein were assessed after single-agent dosing and decreased expression was observed in 2 of 5 patients with sufficient material for analysis. Although some biological activity was observed, the combination of EZN-3042 with intensive reinduction chemotherapy was not tolerated at a dose that led to consistent downregulation of survivin expression. The trial was terminated following the completion of dose level 1, after further clinical development of this agent was halted.

SUBMITTER: Raetz EA 

PROVIDER: S-EPMC4238428 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

Raetz Elizabeth A EA   Morrison Debra D   Romanos-Sirakis Eleny E   Gaynon Paul P   Sposto Richard R   Bhojwani Deepa D   Bostrom Bruce C BC   Brown Patrick P   Eckroth Elena E   Cassar Jeannette J   Malvar Jemily J   Buchbinder Aby A   Carroll William L WL  

Journal of pediatric hematology/oncology 20140801 6


To address the therapeutic challenges in childhood relapsed ALL, a phase 1 study combining a survivin mRNA antagonist, EZN-3042, with reinduction chemotherapy was developed for pediatric patients with second or greater bone marrow relapses of B-lymphoblastic leukemia. EZN-3042 was administered as a single agent on days -5 and -2 and then in combination with a 4-drug reinduction platform on days 8, 15, 22, and 29. Toxicity and the biological activity of EZN-3042 were assessed. Six patients were e  ...[more]

Similar Datasets

| S-EPMC8986610 | biostudies-literature
| S-EPMC10854518 | biostudies-literature
| S-EPMC7477726 | biostudies-literature
| S-EPMC9424077 | biostudies-literature
| S-EPMC6877745 | biostudies-literature
| S-EPMC9345661 | biostudies-literature
| S-EPMC10405914 | biostudies-literature
| S-EPMC3652629 | biostudies-other
| S-EPMC2817627 | biostudies-literature